Skye Bioscience (SKYE)

• Market cap: $23.1M
• 1 day: -0.55%
• 5 days: -11.13%
• 1 month: -23.39%
• 3 months: -52.57%
• 6 months: -77.82%
• Year to date: -17.9%
• 1 year: -74.7%
• 5 years: -94.32%
• 10 years: -94.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 16